^
    1d
    Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    CBX3 promotes epithelial-mesenchymal transition in synovial sarcoma via the SHH signaling pathway. (PubMed, Am J Cancer Res)
    Mechanistically, CBX3 binds directly to and SHH and prevents its ubiquitin-mediated degradation, thereby stabilizing the protein. CBX3-SHH subsequently suppresses mitochondrial oxidative metabolism, which in turn inhibits ferroptosis and facilitates EMT - ultimately promoting SS aggressiveness.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • SHH (Sonic Hedgehog Signaling Molecule) • CBX3 (Chromobox 3)
    2d
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Washington University School of Medicine | Trial completion date: May 2028 --> Jul 2026
    Trial completion date
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    2d
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    pegylated liposomal doxorubicin • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    3d
    PRIME: Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor (clinicaltrials.gov)
    P1/2, N=195, Active, not recruiting, Grupo Espanol de Investigacion en Sarcomas | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ecubectedin (PM14)
    5d
    EXPRESS: Feline tarsal tumors: histologic spectrum, risk factors, and prognostic insights. (PubMed, J Feline Med Surg)
    Risk factors may include male sex, older age, and previous tarsal trauma. A standardized IHC panel combined with a diagnostic algorithm improved histotyping accuracy and should be adopted in clinical practice.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • ITGB2 (Integrin Subunit Beta 2)
    5d
    ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival. (PubMed, ESMO Rare Cancers)
    ATRX mutational status may serve as a potential biomarker for prognosis and therapeutic stratification. Future clinical trials investigating epigenetic therapies could offer novel treatment strategies for ATRX-deficient sarcomas.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler)
    5d
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    5d
    Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Avastin (bevacizumab) • doxorubicin hydrochloride
    6d
    Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. (PubMed, Nat Med)
    Here we provide the basis for further development of trabectedin/irinotecan for patients with ES by the international cooperative groups. ClinicalTrials.gov: NCT04067115 .
    P1/2 data • Journal
    |
    FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    irinotecan • Yondelis (trabectedin)
    6d
    Revealing novel subtypes of synovial sarcoma through single cell transcriptomics. (PubMed, NPJ Syst Biol Appl)
    The biphasic EPCAM+ SyS has the highest levels of differentiation and lowest levels of the core oncogenic program. Our data complements the traditional classification of SyS and suggests that the monophasic mesenchymal SyS might consist of two molecular subtypes.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • HOXD11 (Homeobox D11) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    7d
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=32 --> 48 | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T